Table 1.

Characterization of C. albicans isolates obtained from patients 7, 14, 43, 9, and 40 treated with fluconazole

Patient and isolateSample collection date (mo/day/yr)FLU dosea (mg/day)MIC (μg/ml)bLD50 (106 CFU/mouse) at 8 daysDNA strain identity
24 h48 h
Patient 7
 4122/15/95100<0.1250.59A
 19079/13/95200486A
 230711/22/95400>128>12850A
Patient 14
 5803/13/95100<147B
 6493/20/952004160.7B
 24381/3/962001632>50B
Patient 43
 16497/19/951000.250.252.4C
 18319/1/9510048>50C
 218310/27/95100 (F)c 32>128>50C
Patient 9
 4372/16/951000.510.5D
 10024/18/951000.250.253.4D
 14426/15/95100≤0.125≤0.1250.3D
 227111/6/951008161.9D
 28234/2/9680032160.6D
Patient 40
 16227/10/951000.50.51.3E
 222511/2/95200440.9E
 251212/21/9580032322.1E
  • a FLU dose, fluconazole dose required to suppress thrush.

  • b MICs of fluconazole in macrobroth culture after 24 or 48 h of incubation.

  • c (F), failed 100 mg of fluconazole/day when this isolate was obtained.